SenderraRx, a Dallas-based specialty pharmacy focused on patients with complex and chronic conditions, has received a growth investment from Nautic Partners.
SenderraRx’s management team will retain a significant ownership stake and continue to lead the company, the company said in an announcement. Financial terms were not disclosed.
The investment comes as SenderraRx continues to scale nationally amid rising demand for specialty therapies that require high-touch patient support.
Founded in 2010, SenderraRx has built its business around therapies for patients with complex and chronic conditions, including dermatology, rheumatology, and oncology. Specialty pharmacies typically manage medications that require careful coordination, monitoring, and patient education.
The company has posted rapid growth in recent years, landing on the 2025 Inc. 5000 list for the second consecutive year after reporting more than 60% annual revenue growth over a three-year period. SenderraRx crossed a $1 billion revenue milestone in 2021 and has expanded its national footprint, including the opening of a new distribution center in Plano in 2023, according to a prior company announcement.
The company said the partnership with Nautic will support continued investment in patient services, technology, and operational scale across the U.S.
“We are thrilled to partner with Nautic, whose proven experience in healthcare has the potential to supercharge our expanding access to life-changing therapies and elevate the patient experience,” Will Howard, CEO and co-founder of SenderraRx, said in a statement.
Howard said the partnership aligns with the company’s mission to deliver personalized, patient-centered care. “Together, we’re poised to make an even greater impact in the lives of those we serve,” he said.

Senderra co-founders Win Purifoy, Will Howard, and Tom Bohannon celebrating the company’s anniversary in 2024. [Courtesy photo]
Nautic, a middle-market private equity firm focused on healthcare and related industries, said SenderraRx’s patient-first model and clinical relationships were key factors in the investment.
“SenderraRx exemplifies the patient-first approach that we believe defines the future of specialty pharmacy,” said Keith Farrow, a managing director at Nautic. “We’re excited to support Will and the team as they continue to innovate and grow.”
Joe Anderson, a principal at Nautic, pointed to the company’s network of clinical and pharmaceutical partners. “We have been impressed with the depth of SenderraRx’s relationships with leading clinicians and pharmaceutical partners,” he said.
The transaction is expected to close in the first quarter of 2026.
Cantor Fitzgerald served as financial advisor and Bass, Berry & Sims served as legal advisor to SenderraRx. McDermott, Will & Schutte served as legal advisor to Nautic.
Don’t miss what’s next. Subscribe to Dallas Innovates.
Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.



![A slide showing Tremedics' award-winning technology for treating narrowed aortas in children (left). Their special dissolving stent (right) opens blocked blood vessels and then disappears as the child grows, eliminating the need for repeated surgeries and potentially helping thousands of the 40,000 U.S. babies born with heart defects annually. [Image source: Tremedics]](https://s24806.pcdn.co/wp-content/uploads/2025/05/Tremedic-presentation-970x464.jpg)









